<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02375048</url>
  </required_header>
  <id_info>
    <org_study_id>1288</org_study_id>
    <nct_id>NCT02375048</nct_id>
  </id_info>
  <brief_title>Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI</brief_title>
  <official_title>Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: Adjuvant Hypofractionated Whole Breast Irradiation (WBI) Versus Accelerated Partial Breast Irradiation (APBI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selected patients with early stage breast cancer undergone conservative surgery were&#xD;
      randomized in two arms: Hypofractionated Whole Breast Irradiation versus Accelerated Partial&#xD;
      Breast Irradiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients treated with Hypofractionated Whole Breast Irradiation (WBI) received SIB&#xD;
      irradiation of the whole breast and surgical bed at two different dose levels. Dose&#xD;
      prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with&#xD;
      simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively.&#xD;
      Daily image guided radiotherapy (IGRT) were generated before each treatment session in each&#xD;
      patient to verify the set-up.&#xD;
&#xD;
      Accelerated Partial Breast Irradiation (APBI) using external intensity -modulated&#xD;
      radiotherapy (VMAT RA) was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10&#xD;
      days (every other day) with IGRT at each treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    number of enrollments not reached in the estimated time&#xD;
  </why_stopped>
  <start_date type="Actual">January 19, 2015</start_date>
  <completion_date type="Actual">February 1, 2018</completion_date>
  <primary_completion_date type="Actual">February 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity will be measured with CTCAE v.4.0</measure>
    <time_frame>ten years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cosmesis will be measured with Harvard scale</measure>
    <time_frame>ten years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Local Control</measure>
    <time_frame>ten years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>ten years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>ten years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire</measure>
    <time_frame>ten years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Cancer of Breast</condition>
  <arm_group>
    <arm_group_label>Hypofractionated WBI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with hypofractionated Whole Breast Irradiation received Simultaneous Integrated Boost irradiation of the whole breast and surgical bed at two different dose levels using external intensity - modulated radiotherapy (VMAT RA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accelerated Partial Breast Irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with Accelerated Partial Breast Irradiation received the irradiation on surgical bed using external intensity - modulated radiotherapy (VMAT RA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated WBI</intervention_name>
    <description>Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.</description>
    <arm_group_label>Hypofractionated WBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Accelerated Partial Breast Irradiation</intervention_name>
    <description>APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.</description>
    <arm_group_label>Accelerated Partial Breast Irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  55&lt; Age &lt;70&#xD;
&#xD;
          -  Tumor size â‰¤ 2 cm&#xD;
&#xD;
          -  pN0 (SN biopsy or ALND)&#xD;
&#xD;
          -  ER/PgR positive&#xD;
&#xD;
          -  Margins &gt; 5 mm (either at initial surgery or at re-excision)&#xD;
&#xD;
          -  Clips placed in the surgical bed (minimum of 4 clips)&#xD;
&#xD;
          -  Unicentric only&#xD;
&#xD;
          -  No lymphovascular invasion&#xD;
&#xD;
          -  Any grade&#xD;
&#xD;
          -  No extensive intraductal component (&gt;25%)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior thoracic radiation therapy&#xD;
&#xD;
          -  Oncoplastic surgery / No clips in the surgical bed&#xD;
&#xD;
          -  Multicentric cancer&#xD;
&#xD;
          -  Autoimmune disease, vasculitis, collagenopathy or scleroderma that may predispose to&#xD;
             late sequelae&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Scorsetti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2015</study_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

